Investigation of TORCH seroprevalence in a tertiary university hospital

This study aimed to investigate the seroprevalence of TORCH (Toxoplasma gondii, other agents, Rubella, Cytomegalovirus (CMV), and herpes simplex virus (HSV)) in pregnant women at a tertiary university hospital and determine the level of immunity in the community. This retrospective study included 1,...

Full description

Saved in:
Bibliographic Details
Main Author: Samet Kirat
Format: Article
Language:English
Published: Society of Turaz Bilim 2024-04-01
Series:Medicine Science
Subjects:
Online Access:https://www.medicinescience.org/?mno=224306
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1825206519051845632
author Samet Kirat
author_facet Samet Kirat
author_sort Samet Kirat
collection DOAJ
description This study aimed to investigate the seroprevalence of TORCH (Toxoplasma gondii, other agents, Rubella, Cytomegalovirus (CMV), and herpes simplex virus (HSV)) in pregnant women at a tertiary university hospital and determine the level of immunity in the community. This retrospective study included 1,556 pregnant women aged 18-50 years who visited the Department of Obstetrics and Gynecology between January 2022 and January 2024. Demographic data and TORCH antibody test results were collected from medical records. Seroprevalence rates were compared between the 18-35 and 35-50 age groups. Avidity test results were recorded for pregnant women with positive IgM antibodies against Toxoplasma, Rubella, and CMV. Seroprevalence rates were Toxoplasma IgM (0.3%), Toxoplasma IgG (76%), Rubella IgM (0.4%), Rubella IgG (96.7%), CMV IgM (0.2%), CMV IgG (97.2%), HSV IgG (97.8%), HBsAg (0.6%), Anti-HBs (18.1%), Anti-HCV (0.3%), and Anti-HIV (0.1%). The frequency of previous infections and proportion of vaccinated individuals increased in pregnant women aged 35-50 years. Avidity tests were performed on pregnant women with positive IgM antibodies against Toxoplasma, Rubella, and CMV to confirm the primary infection. The seroprevalence of TORCH infections in pregnant women at a tertiary university hospital was determined, with a higher proportion of previous infections and immunized individuals in the older age group. The results highlight the importance of prenatal screening for TORCH infections to prevent potential complications and guide health policies for infection control strategies. [Med-Science 2024; 13(4.000): 995-1000]
format Article
id doaj-art-d98ee3d4ffe3450fa3224b8a3b5e6717
institution Kabale University
issn 2147-0634
language English
publishDate 2024-04-01
publisher Society of Turaz Bilim
record_format Article
series Medicine Science
spelling doaj-art-d98ee3d4ffe3450fa3224b8a3b5e67172025-02-07T08:49:24ZengSociety of Turaz BilimMedicine Science2147-06342024-04-01134995100010.5455/medscience.2024.10.127224306Investigation of TORCH seroprevalence in a tertiary university hospitalSamet Kirat0Academic Department of Obstetrics and Gynecology, Kafkas University School of Medicine, Kars, TURKEYThis study aimed to investigate the seroprevalence of TORCH (Toxoplasma gondii, other agents, Rubella, Cytomegalovirus (CMV), and herpes simplex virus (HSV)) in pregnant women at a tertiary university hospital and determine the level of immunity in the community. This retrospective study included 1,556 pregnant women aged 18-50 years who visited the Department of Obstetrics and Gynecology between January 2022 and January 2024. Demographic data and TORCH antibody test results were collected from medical records. Seroprevalence rates were compared between the 18-35 and 35-50 age groups. Avidity test results were recorded for pregnant women with positive IgM antibodies against Toxoplasma, Rubella, and CMV. Seroprevalence rates were Toxoplasma IgM (0.3%), Toxoplasma IgG (76%), Rubella IgM (0.4%), Rubella IgG (96.7%), CMV IgM (0.2%), CMV IgG (97.2%), HSV IgG (97.8%), HBsAg (0.6%), Anti-HBs (18.1%), Anti-HCV (0.3%), and Anti-HIV (0.1%). The frequency of previous infections and proportion of vaccinated individuals increased in pregnant women aged 35-50 years. Avidity tests were performed on pregnant women with positive IgM antibodies against Toxoplasma, Rubella, and CMV to confirm the primary infection. The seroprevalence of TORCH infections in pregnant women at a tertiary university hospital was determined, with a higher proportion of previous infections and immunized individuals in the older age group. The results highlight the importance of prenatal screening for TORCH infections to prevent potential complications and guide health policies for infection control strategies. [Med-Science 2024; 13(4.000): 995-1000]https://www.medicinescience.org/?mno=224306cytomegalovirusherpes simplexrubellaseroprevalencetoxoplasma
spellingShingle Samet Kirat
Investigation of TORCH seroprevalence in a tertiary university hospital
Medicine Science
cytomegalovirus
herpes simplex
rubella
seroprevalence
toxoplasma
title Investigation of TORCH seroprevalence in a tertiary university hospital
title_full Investigation of TORCH seroprevalence in a tertiary university hospital
title_fullStr Investigation of TORCH seroprevalence in a tertiary university hospital
title_full_unstemmed Investigation of TORCH seroprevalence in a tertiary university hospital
title_short Investigation of TORCH seroprevalence in a tertiary university hospital
title_sort investigation of torch seroprevalence in a tertiary university hospital
topic cytomegalovirus
herpes simplex
rubella
seroprevalence
toxoplasma
url https://www.medicinescience.org/?mno=224306
work_keys_str_mv AT sametkirat investigationoftorchseroprevalenceinatertiaryuniversityhospital